Document Mentions (4 shared documents)

EFTA02454468

2 mentions1 same-page

Page ?Same page

ue to its healthy product mix, solid pipe=ine and flexibility to deploy capital to drive shareholder return. N=xt catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm :=17;s US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval=of

High Strike Current Yield Yield Advantage over Stock BAML Ranking (Stock) BAML Price Tgt (Stock) Stock Upside to Price Tgt S=ock Up 25%: Pfd Return S=ock Down 25%: Pfd Return N=tional Outstanding AGN =AGNprA) 5.5% 3/1/18 252.95 893.45 288.00 4 EFTA_R1_01556245 EFTA02454471 352.80 6.2%

EFTA02454699_email_004

2 mentions1 same-page

Page ?Same page

ue to its healthy product mix, solid pipeline and flexibility to deploy capital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN g

11 EFTA_R1_01556638 EFTA02454709 Ranking (Stock) BAML Price Tgt (Stock) Stock Upside to Price Tgt Stock Up 25%: Pfd Return Stock Down 25%: Pfd Return Notional Outstanding AGN (AGNprA) 5.5% 3/1/18 252.95 893.45 288.00 352.80 6.2% 6.2% 1 - Buy $ 294.00 16.2% 22.7% -15.5% S5.06bn TEVA

EFTA02454261_email_005

2 mentions1 same-page

Page ?Same page

d Yield Advantage over Stock BAML Ranking (Stock) BAML Price Tgt (Stock) Stock Upside to Price Tgt Stock Up 25%: Pfd Return Stock Down 25%: Pfd Return Notional Outstanding AGN (AGNprA) 5.5% 3/1/18 11 EFTA_R1_01555899 EFTA02454271 252.95 893.45 288.00 352.80 6.2% 6.2% 1 - Buy $ 294.00